Products - Breast cancer | Topic

Showing 19 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2026
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2027
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Artificial intelligence technologies for mammography: early value assessment
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital AI tools in histopathology (breast and prostate cancer)
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Breast cancer Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 19 products

Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]

Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]

Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620]

Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]

Artificial intelligence technologies for mammography: early value assessment

Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

Digital AI tools in histopathology (breast and prostate cancer)

Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

Breast cancer Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 19 products

Status
1 selected